Shaily Engineering Plastics Ltd Q1 FY27 Earnings Analysis

- Healthcare segment revenue grew 139% in FY26 to INR393 crores, driven by pen injector ramp-up and GLP-1 product launches in India, Canada, and upcoming other countries. - Pen injector order of INR423 crores is spread over 4 years, with regular supplies expected to ramp up. - Total pen injector capacity expected to reach 80 million pens by July-August FY27, targeting 36 million pens supply in FY27 and around 50 million pens in FY28. - Full utilization of pen injector capacity anticipated within next 2-3 years, with healthcare segment expected to sustain strong growth. - Consumer segment declined 9% in FY26 but expected to recover as global demand improves; new products being added to consumer space. - Industrial segment growing steadily with 41% growth in FY26. - Overall, company targets ~25% consolidated top-line growth, dependent on healthcare ramp-up and consumer recovery.

- FY26 marked by smooth execution and improved operational performance; confident of profitable, sustainable growth in coming years (Amit Sanghvi, closing remarks). - Healthcare vertical expected to continue scaling with GLP-1 product launches in India, Canada, and other countries driving regular supply ramp-up. - Consumer segment will depend on global demand recovery; new product additions in consumer electronics and semiconductor trays aim to restore growth momentum. - Capacity additions (50 million pens planned by July/August) should enable healthcare revenue growth but exact quarterly run rate guidance not disclosed. - UK subsidiary margins expected to be maintained over long term with focus on advanced device projects; combined UK and UAE operations should deliver stable margins. - Operating efficiencies improving; machine utilization up to 47.6% in FY26 from 42.2% last year. - Management expects growth bounce back in consumer segment and continuation of healthcare growth to sustain consolidated top-line growth around 25%.

- The company is evaluating setting up a new plant for consumer electronics, with an initial estimated capex of around INR 100 crores. - Additional substantial capex is expected for scaling new device capacities, including healthcare-related projects that cannot be serviced from existing sites like India or Abu Dhabi. - A capital raising resolution is in place as an enablement option for time-sensitive, capital-intensive projects, though no immediate capital is being raised. - There is ongoing investment in the new pen injector production lines, with capacity being added (25 million pens added in March, another 25 million expected by July-August). - Expansion plans include increasing operational efficiency and capacity utilization, targeting 35-40 million pens in supply by FY28. - The company is progressing with projects in Abu Dhabi to leverage operational cost advantages and global talent availability.

- Currently, Shaily Engineering Plastics Limited is not raising any capital immediately; the recent resolution for fundraise is an enablement option for future needs. - The company is preparing for potential large-scale, time-sensitive, capital-intensive projects, especially for additional device manufacturing capacities. - If such an opportunity arises, they want the ability to quickly raise capital, either through debt or equity, as this would require substantial one-off capex. - There is no mention of an ongoing or imminent fundraising, but readiness is maintained to act swiftly if required.

- The company has a recently announced INR 423 crore pen injector order spread over 4 years (Q4 FY26 transcript). - The order is incremental and for pen injector supplies over 4 years. - For FY27, guidance is around 36 million pens for pen injector supplies. - Existing capacity for pen injectors is 30 million pens; an additional 25 million was added in March and another 25 million expected by July/August, totaling 80 million pens capacity. - The healthcare revenue ramp-up is expected with new product launches in India, Canada, and upcoming launches in other countries. - The consumer segment saw a decline and is expected to recover as global demand improves. - Semiconductor trays order currently from a Korean client with plans to supply to other semiconductor manufacturers in India. - UK subsidiary focusing on longer-term projects; revenue growth expected over time but currently with lower quarter margins. Overall, orderbook includes the INR 423 crore pen injector order plus ongoing orders in healthcare and semiconductor segments.